Biotech Overbought Stocks: Agenus Inc. (NASDAQ:AGEN), Biota Pharmaceuticals (NASDAQ:BOTA), Albany Molecular Research (NASDAQ:AMRI), Sunesis Pharmaceuticals (NASDAQ:SNSS)

Agenus Inc. (NASDAQ:AGEN) will release its fourth quarter and year end 2013 financial results before the market opens on March 5, 2014. Agenus Inc. (NASDAQ:AGEN) stock performance was 0.00% in last session and finished the day at $4.89. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 1.12 million shares. The beta of the stock remained 1.33. … Continue reading Biotech Overbought Stocks: Agenus Inc. (NASDAQ:AGEN), Biota Pharmaceuticals (NASDAQ:BOTA), Albany Molecular Research (NASDAQ:AMRI), Sunesis Pharmaceuticals (NASDAQ:SNSS)

Healthcare Insider Buying: Opko Health (NYSE:OPK), American Apparel (NYSEMKT:APP), Accelerate Diagnostics Inc (NASDAQ:AXDX), Biota Pharmaceuticals Inc (NASDAQ:BOTA), Echo Therapeutics Inc (NASDAQ:ECTE)

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 30,000 shares of the stock in a transaction dated Tuesday, July 8th. The shares were purchased at an average price of $8.58 per share, for a total transaction of $257,400.00. Following the completion of the transaction, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $17,052,750. Opko Health Inc. … Continue reading Healthcare Insider Buying: Opko Health (NYSE:OPK), American Apparel (NYSEMKT:APP), Accelerate Diagnostics Inc (NASDAQ:AXDX), Biota Pharmaceuticals Inc (NASDAQ:BOTA), Echo Therapeutics Inc (NASDAQ:ECTE)

Biotech Insider Buying: Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Cytori Therapeutics (NASDAQ:CYTX), Oramed Pharmaceuticals (NASDAQ:ORMP), Biota Pharmaceuticals (NASDAQ:BOTA)

Seattle Genetics, Inc (NASDAQ:SGEN) Director Felix Baker purchased 281,963 shares of Seattle Genetics stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average price of $34.86 per share, for a total transaction of $9,829,230.18. Following the transaction, the director now directly owns 76,997 shares of the company’s stock, valued at approximately $2,684,115. Seattle Genetics, Inc. (NASDAQ:SGEN) stock performance was -0.05% … Continue reading Biotech Insider Buying: Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Cytori Therapeutics (NASDAQ:CYTX), Oramed Pharmaceuticals (NASDAQ:ORMP), Biota Pharmaceuticals (NASDAQ:BOTA)